Form 4: Pacira BioSciences CEO Frank D. Lee Acquires 8,264 Shares of Common Stock
SEC Form 4 Filing
Pacira BioSciences CEO Frank D. Lee purchased 8,264 shares of common stock at $12.1 per share on August 12, 2024.
Summary
- On August 12, 2024, Frank D. Lee, the CEO of Pacira BioSciences, Inc. (PCRX), acquired 8,264 shares of common stock.
- The purchase price was $12.1 per share.
- Following the transaction, Lee directly owns 107,784 shares of Pacira BioSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an insider transaction. The CEO buying shares is generally a positive sign, but without more context, it's difficult to gauge the significance.
Positives
- The CEO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Insider trading activity is often monitored by investors as it can provide insights into management's perspective on the company's valuation and future performance. Purchases by executives can be seen as a positive signal.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of transaction: Frank D. Lee purchased 8,264 shares of common stock. |
| 08/13/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.